专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022203090A1 COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2022203090A1
公开(公告)日：2022-09-29
申请号：PCT/JP2022/017017
申请日：2022-03-24
申请人： ASTELLAS PHARMA INC.
发明人： BHATTACHARYA, Pranob P. , WENG, Jane , KINUGASA, Fumitaka
IPC分类号： A61K33/00 , A61K39/395 , C07K16/28
摘要： The present invention provides a combination therapy for treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

2. 发明申请

WO2022054965A1 COMPOUND FOR USE IN THE TREATMENT OF DRY MOUTH 审中-公开
公开(公告)号：WO2022054965A1
公开(公告)日：2022-03-17
申请号：PCT/JP2021/034445
申请日：2021-09-13
申请人： ASTELLAS PHARMA INC.
发明人： DE VRIES, Michiel Henricus , GROENENDAAL, Dorien
IPC分类号： A61K31/497 , A61K31/4178 , A61K45/06 , A61P43/00
摘要： The present invention is concerned with the use of compound in the treatment of dry mouth.

3. 发明申请

WO2020101042A1 METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING UTROPHIN GENE 审中-公开
公开(公告)号：WO2020101042A1
公开(公告)日：2020-05-22
申请号：PCT/JP2019/045716
申请日：2019-11-15
申请人： ASTELLAS PHARMA INC. , MODALIS THERAPEUTICS CORPORATION
发明人： YOSHIMI, Eiji , YOSHIOKA, Katsuro , YAMAGATA, Tetsuya , QUIN, Yuanbo , THOMPSON, Iain Robert , KHANNA, Nidhi
IPC分类号： A61K48/00 , C07K14/47 , C12N9/22 , C12N15/113 , C12N15/86
摘要： Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.

4. 发明申请

WO2013018362A1 2-ACYLAMINOTHIAZOLE COMPOUND CRYSTALS 审中-公开
标题翻译： 2-氨基苯并噻唑化合物
公开(公告)号：WO2013018362A1
公开(公告)日：2013-02-07
申请号：PCT/JP2012/004885
申请日：2012-08-01
申请人： ASTELLAS PHARMA INC. , SUGASAWA, Keizo , MIYAFUJI, Akio , SUZUKI, Kenichi , AWAMURA, Yuji
发明人： SUGASAWA, Keizo , MIYAFUJI, Akio , SUZUKI, Kenichi , AWAMURA, Yuji
IPC分类号： C07D417/14 , A61K31/496 , A61P7/04
CPC分类号： C07D417/14
摘要： The purpose of the present invention is to provide crystals of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexyl piperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt that can ensure constant quality and constant effects as a drug substance for medicines, and that can be stably supplied in mass production such as industrial production. The present invention relates to crystals of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexyl piperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt with endothermic peak top temperatures in differential scanning calorimeter analysis of between approximately 229 and 232 degree C, and between approximately 300 and 303 degree C. The crystals of the present invention are with excellent oral absorption, can be stably supplied in mass production such as industrial production or the like, and can be used as an active ingredient in a pharmaceutical composition for preventing and/or treating various types of thrombocytopenia.
摘要翻译：本发明的目的是提供1-（3-氯-5 - {[4-（4-氯噻吩-2-基）-5-（4-环己基哌嗪-1-基）噻唑-2-基] 吡啶-2-基）哌啶-4-甲酸马来酸盐，其能够确保作为药物的药物的质量和恒定的效果，并且可以在大规模生产例如工业生产中稳定供应。本发明涉及1-（3-氯-5 - {[4-（4-氯噻吩-2-基）-5-（4-环己基哌嗪-1-基）噻唑-2-基]氨基甲酰基} 吡啶-2-基）哌啶-4-甲酸马来酸盐，差示扫描量热分析仪的吸热峰顶温度在229和232摄氏度之间，在约300和303摄氏度之间。本发明的晶体是具有优异的口服吸收性，可以在工业化生产等的批量生产中稳定供给，可以作为预防和/或治疗各种血小板减少症的药物组合物中的活性成分使用。

5. 发明申请

WO2012170839A2 TREATMENT OF NEUROINFLAMMATORY DISEASE WITH SELECTIVE COX1 INHIBITORS 审中-公开
标题翻译：用选择性COX1抑制剂治疗神经炎症性疾病
公开(公告)号：WO2012170839A2
公开(公告)日：2012-12-13
申请号：PCT/US2012/041586
申请日：2012-06-08
申请人： CARDEUS PHARMACEUTICALS, INC. , ASTELLAS PHARMA, INC. , BRUNKE, Karen, J. , CAUFIELD, John , NII, Keni , OHMIYA, Makoto
发明人： BRUNKE, Karen, J. , CAUFIELD, John , NII, Keni , OHMIYA, Makoto
IPC分类号： A61K31/4196 , C07D249/08 , A61P29/00 , A61P25/00
CPC分类号： A61K31/4439 , A61K31/4196 , C07D249/12
摘要： Highly selective COX1 inhibitors can be used to treat a neuroinflammatory disease.
摘要翻译：高选择性COX1抑制剂可用于治疗神经炎症性疾病。

6. 发明申请

WO2012054510A1 OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF 审中-公开
标题翻译：抑制β-分泌酶活性的OXADIAZOLE化合物及其使用方法
公开(公告)号：WO2012054510A1
公开(公告)日：2012-04-26
申请号：PCT/US2011/056747
申请日：2011-10-18
申请人： COMENTIS, INC. , ASTELLAS PHARMA INC. , BILCER, Geoffrey, M. , DEVASAMUDRAM, Thippeswamy , LILLY, John, C. , ANKALA, Sudha, V. , MOSKALEV, Nikolai, V. , LIU, Chunfeng , INOUE, Makoto , KAWAKAMI, Shimpei , MUNAKATA, Ryosuke , HAMAJIMA, Toshihiro
发明人： BILCER, Geoffrey, M. , DEVASAMUDRAM, Thippeswamy , LILLY, John, C. , ANKALA, Sudha, V. , MOSKALEV, Nikolai, V. , LIU, Chunfeng , INOUE, Makoto , KAWAKAMI, Shimpei , MUNAKATA, Ryosuke , HAMAJIMA, Toshihiro
IPC分类号： C07D417/14 , A61K31/427 , C07D413/12 , A61K31/422 , A61K31/4439 , C07D413/14 , A61K31/4245 , A61P25/28
CPC分类号： C07D413/12 , C07D413/14 , C07D417/14
摘要： The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.
摘要翻译：本发明提供新颖的β-分泌酶抑制剂及其包括治疗阿尔茨海默氏病的方法。

7. 发明申请

WO2012024419A3 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA 审中-公开
公开(公告)号：WO2012024419A3
公开(公告)日：2012-02-23
申请号：PCT/US2011/048110
申请日：2011-08-17
申请人： ALCON RESEARCH, LTD. , ASTELLAS PHARMA INC. , COMBRINK, Keith D. , MOHAPATRA, Suchismita , HELLBERG, Mark R. , SHARIF, Najam A. , PRASANNA, Ganesh , PANG, Iok-Hou , SEVERNS, Bryon , CHEN, Hwang-Hsing , NAMIL, Abdelmoula
发明人： COMBRINK, Keith D. , MOHAPATRA, Suchismita , HELLBERG, Mark R. , SHARIF, Najam A. , PRASANNA, Ganesh , PANG, Iok-Hou , SEVERNS, Bryon , CHEN, Hwang-Hsing , NAMIL, Abdelmoula
IPC分类号： C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D498/04 , A61K31/4427 , A61K31/444 , A61K31/4709 , A61K31/4184 , A61P27/06
摘要： The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds arc bradykinin agonists, of formula (I).

8. 发明申请

WO2007091703A1 N-HYDROXYACRYLAMIDE COMPOUNDS 审中-公开
标题翻译： N-羟基丙烯酰胺化合物
公开(公告)号：WO2007091703A1
公开(公告)日：2007-08-16
申请号：PCT/JP2007/052447
申请日：2007-02-06
申请人： ASTELLAS PHARMA INC. , SHIRAI, Fumiyuki , TSUTSUMI, Hideo , ITANI, Hiromichi , KOZUKI, Yoshihiro , EIKYU, Yoshiteru , MASUNAGA, Taro
发明人： SHIRAI, Fumiyuki , TSUTSUMI, Hideo , ITANI, Hiromichi , KOZUKI, Yoshihiro , EIKYU, Yoshiteru , MASUNAGA, Taro
IPC分类号： C07D403/12 , C07D401/12 , A61K31/496 , A61P35/00
CPC分类号： C07D409/14 , C07D401/12 , C07D403/12
摘要： This invention relates to novel N-hydroxyacrylamide compounds of formula (I) and pharmaceutically acceptable salts thereof . More particularly, it relates to novel N-hydroxyacrylamide compounds and pharmaceutically acceptable salts thereof which act as a HDAC inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of HDAC- related disease.
摘要翻译：本发明涉及式（I）的新型N-羟基丙烯酰胺化合物及其药学上可接受的盐。更具体地说，本发明涉及作为HDAC抑制剂的新型N-羟基丙烯酰胺化合物及其药学上可接受的盐，涉及包含其的药物组合物，以及在治疗和/或预防HDAC相关性中使用该N-羟基丙烯酰胺化合物的方法疾病。

9. 发明申请

WO2007049803A1 NEW CYCLIC PEPTIDE COMPOUNDS 审中-公开
标题翻译：新型循环肽化合物
公开(公告)号：WO2007049803A1
公开(公告)日：2007-05-03
申请号：PCT/JP2006/321924
申请日：2006-10-26
申请人： Astellas Pharma Inc. , NEYA, Masahiro , YOSHIMURA, Seiji , KAMIJYO, Kazunori , MAKINO, Takuya , YASUDA, Minoru , YAMANAKA, Toshio , TSUJII, Eisaku , YAMAGISHI, Yukiko
发明人： NEYA, Masahiro , YOSHIMURA, Seiji , KAMIJYO, Kazunori , MAKINO, Takuya , YASUDA, Minoru , YAMANAKA, Toshio , TSUJII, Eisaku , YAMAGISHI, Yukiko
IPC分类号： C07K7/64 , A61P31/12
CPC分类号： C07K7/645 , A61K38/00
摘要： The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising, the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
摘要翻译：本发明涉及一种具有抗丙型肝炎病毒复制子的RNA复制的抑制活性的抗丙型肝炎病毒活性的新的环肽化合物或其盐，涉及其制备方法，其包括在温和酸性条件和以下氨基酸变化反应等，涉及包含其的药物组合物，以及用于预防和/或治疗人或动物中的丙型肝炎的方法。

10. 发明申请

WO2005105147A3 COMBINATION OF PROSTAGLANDIN E2 RECEPTOR ANTAGONISTS AND RENIN-ANGIOTENSIN SYSTEM INHIBITORS FOR TREATING RENAL DISEASES 审中-公开
标题翻译：前列腺素E2受体拮抗剂的组合和用于治疗肾病的瑞恩 - 血管紧张素系统抑制剂
公开(公告)号：WO2005105147A3
公开(公告)日：2006-11-30
申请号：PCT/JP2005006536
申请日：2005-03-28
申请人： ASTELLAS PHARMA INC , SOGABE HAJIME , TOMITA MASAYUKI , NAKAZATO SHOKO
发明人： SOGABE HAJIME , TOMITA MASAYUKI , NAKAZATO SHOKO
IPC分类号： A61K45/06 , A61K31/401 , A61K31/421 , A61P13/12
CPC分类号： A61K45/06 , A61K31/401 , A61K31/421 , A61K2300/00
摘要： This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor.
摘要翻译：本发明涉及通过使用前列腺素E2受体拮抗剂和肾素 - 血管紧张素系统抑制剂的组合治疗肾病的方法和用于治疗包含前列腺素E2受体拮抗剂和肾素 - 血管紧张素系统抑制剂的肾病的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式